Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design
With the deepening of our understanding of adaptive immunity at the cellular and molecular level, targeting antigens directly to immune cells has proven to be a successful strategy to develop innovative and potent vaccines. Indeed, it offers the potential to increase vaccine potency and/or modulate immune response quality while reducing off-target effects. With mRNA-vaccines establishing themselves as a versatile technology for future applications, in the last years several approaches have been explored to target nanoparticles-enabled mRNA-delivery systems to immune cells, with a focus on dendritic cells. Dendritic cells (DCs) are the most potent antigen presenting cells and key mediators of B- and T-cell immunity, and therefore considered as an ideal target for cell-specific antigen delivery. Indeed, improved potency of DC-targeted vaccines has been proved in vitro and in vivo. This review discusses the potential specific targets for immune system-directed mRNA delivery, as well as the different targeting ligand classes and delivery systems used for this purpose.
Top-30
Journals
|
1
2
3
4
5
6
|
|
|
Vaccines
6 publications, 15.38%
|
|
|
Pharmaceutics
3 publications, 7.69%
|
|
|
Frontiers in Immunology
1 publication, 2.56%
|
|
|
European Journal of Pharmaceutics and Biopharmaceutics
1 publication, 2.56%
|
|
|
International Immunopharmacology
1 publication, 2.56%
|
|
|
Biomolecules
1 publication, 2.56%
|
|
|
Frontiers in Oncology
1 publication, 2.56%
|
|
|
Molecular Biomedicine
1 publication, 2.56%
|
|
|
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
1 publication, 2.56%
|
|
|
Biotechnology Advances
1 publication, 2.56%
|
|
|
MedComm
1 publication, 2.56%
|
|
|
Clinical Pharmacology and Therapeutics
1 publication, 2.56%
|
|
|
Applied Materials Today
1 publication, 2.56%
|
|
|
Vaccine
1 publication, 2.56%
|
|
|
Chem & Bio Engineering
1 publication, 2.56%
|
|
|
Frontiers in Cellular and Infection Microbiology
1 publication, 2.56%
|
|
|
Advanced Materials
1 publication, 2.56%
|
|
|
Molecular Therapy
1 publication, 2.56%
|
|
|
Current Medicinal Chemistry
1 publication, 2.56%
|
|
|
Life
1 publication, 2.56%
|
|
|
Fish and Shellfish Immunology
1 publication, 2.56%
|
|
|
Gels
1 publication, 2.56%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
1 publication, 2.56%
|
|
|
Hybrid Advances
1 publication, 2.56%
|
|
|
Holistic Integrative Oncology
1 publication, 2.56%
|
|
|
Cancer Innovation
1 publication, 2.56%
|
|
|
1
2
3
4
5
6
|
Publishers
|
2
4
6
8
10
12
|
|
|
MDPI
12 publications, 30.77%
|
|
|
Elsevier
10 publications, 25.64%
|
|
|
Wiley
5 publications, 12.82%
|
|
|
Cold Spring Harbor Laboratory
4 publications, 10.26%
|
|
|
Frontiers Media S.A.
3 publications, 7.69%
|
|
|
Springer Nature
3 publications, 7.69%
|
|
|
American Chemical Society (ACS)
1 publication, 2.56%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 2.56%
|
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.